<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01829880</url>
  </required_header>
  <id_info>
    <org_study_id>GOLNIK_PKT1</org_study_id>
    <nct_id>NCT01829880</nct_id>
  </id_info>
  <brief_title>Impact of Body Composition on Bisoprolol and Ramipril Pharmacokinetics in Patients With Chronic Heart Failure</brief_title>
  <official_title>Impact of Body Composition Changes and Cachexia on Bisoprolol and Ramipril Pharmacokinetics and Renal Function Estimation in Patients With Chronic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University Clinic of Pulmonary and Allergic Diseases Golnik</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University Clinic of Pulmonary and Allergic Diseases Golnik</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if cachexia and changes in body composition
      influence pharmacokinetics of bisoprolol and ramipril and the accuracy of equations for renal
      function estimation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with chronic heart failure on treatment with bisoprolol and/or ramipril will be
      included. Study will consist of two study visits: baseline visit (V1) and visit which will be
      performed at least 6 months after baseline (V2). At both visits same procedures will be
      performed. On the day of the visit, patients will be asked to take their morning dose of
      bisoprolol and/or ramipril after the withdrawal of the first morning plasma sample.
      Additional 3 to 5 plasma samples will be taken within 5 hours post bisoprolol and/or ramipril
      dose in order to determine pharmacokinetic profile of both drugs. Body composition will be
      measured by bioimpedance and dual-energy X-ray absorptiometry. Renal function will be
      measured by clearance of intravenously administered iohexol. Biochemical parameters, muscle
      strength, fatigue and anorexia will be assessed in order to determine presence of cachexia.

      Changes in body composition will be correlated with changes in pharmacokinetic parameters of
      bisoprolol and ramipril. Pharmacokinetic parameters in cachectic patients will be compared to
      pharmacokinetic parameters in non-cachectic patients. Parameters of body composition will be
      correlated with the difference between measured and estimated renal function.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of bisoprolol and ramipril</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Pharmacokinetic parameters of bisoprolol and ramipril(clearance, volume of distribution, area under concentration-time curve, maximal concentration, time to maximal concentration) will be determined. The relation between pharmacokinetic parameters and body composition/cachexia will be assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Body composition (percentage and amount of body fat, lean body mass, dry lean body mass and body water) will be measured by bioimpedance and dual energy X-ray absorptiometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cachexia diagnosis</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Cachexia diagnosis (determination of low body mass index, wasting, biochemical parameters, muscle strength, fatigue and anorexia)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Renal function will be measured by clearance of intravenously applied iohexol. Estimation of renal function will be calculated with different equations based on serum creatinine concentration. Measured and estimated renal function will be compared and the differences related to body composition parameters.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Heart Failure</condition>
  <condition>Cachexia</condition>
  <arm_group>
    <arm_group_label>Chronic heart failure patients</arm_group_label>
    <description>Patients with chronic heart failure who attend to internal medicine outpatient clinic.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma, serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic heart failure who attend internal medicine outpatient clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of chronic heart failure of New York Heart Association Functional
             Classification (NYHA) class II and III

          -  On treatment with bisoprolol for at least 3 days and/or ramipril for at least 4 days
             before V1

          -  Able and willing to provide freely given written informed consent

        Exclusion Criteria:

          -  Chronic renal disease with estimated glomerular filtration rate calculated by
             Modification of Diet in Renal Disease (MDRD) equation &lt; 40 mL/(min x 1,73 m2) at V1 or
             V2

          -  Liver disease or increased serum liver enzymes (bilirubin &gt; 1.5 x normal,
             gamma-glutamyl transpeptidase (GGT) &gt; 2.5 x normal, aspartate transaminase (AST) &gt; 2.5
             x normal, alanine transaminase (ALT) &gt; 2.5 x normal) at V1 or V2

          -  Absence of bisoprolol or ramipril steady state concentrations at V1 or V2 or
             withdrawal of bisoprolol and/or ramipril in-between both visits

          -  Acute decompensation of heart failure in less than 4 weeks before V1 or V2

          -  Addition, withdrawal or change in dose of drugs that importantly influence bisoprolol
             or ramipril pharmacokinetics in-between V1 and V2

          -  Unable to understand and comply with protocol or to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitja Lainscak, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Clinic Golnik</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mitja Lainscak, MD, PhD</last_name>
    <phone>(0) 4 256 9483</phone>
    <phone_ext>+386</phone_ext>
    <email>mitja.lainscak@guest.arnes.si</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katja Trobec, MPharm</last_name>
    <phone>(0) 4 256 9360</phone>
    <phone_ext>+386</phone_ext>
    <email>katja.trobec@klinika-golnik.si</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Clinic of Respiratory and Allergic Diseases Golnik</name>
      <address>
        <city>Golnik</city>
        <zip>4204</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitja Lainscak, MD, PhD</last_name>
      <phone>(0) 4 256 9483</phone>
      <phone_ext>+386</phone_ext>
      <email>mitja.lainscak@guest.arnes.si</email>
    </contact>
    <contact_backup>
      <last_name>Katja Trobec, MPharm</last_name>
      <phone>(0) 4 256 9360</phone>
      <phone_ext>+386</phone_ext>
      <email>katja.trobec@klinika-golnik.si</email>
    </contact_backup>
    <investigator>
      <last_name>Mitja Lainscak, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katja Trobec, MPharm</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2013</study_first_submitted>
  <study_first_submitted_qc>April 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2013</study_first_posted>
  <last_update_submitted>April 8, 2013</last_update_submitted>
  <last_update_submitted_qc>April 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University Clinic of Pulmonary and Allergic Diseases Golnik</investigator_affiliation>
    <investigator_full_name>Mitja Lainščak</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Chronic heart failure</keyword>
  <keyword>Bisoprolol</keyword>
  <keyword>Ramipril</keyword>
  <keyword>Pharmacokinetic</keyword>
  <keyword>Cachexia</keyword>
  <keyword>Body composition</keyword>
  <keyword>Renal function</keyword>
  <keyword>Iohexol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cachexia</mesh_term>
    <mesh_term>Wasting Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramipril</mesh_term>
    <mesh_term>Bisoprolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

